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ABSTRACT 
Objective: Pharmaceutical cocrystal is a promising method to improve the solubility of active pharmaceutical ingredients (APIs). Itraconazole (ITZ) 
is a BCS class II antifungal drug with poor aqueous solubility, therefore an attempt was made to improve the solubility of ITZ using cocrystallization 
technique. In this work, six novel pharmaceutical cocrystals of ITZ with various coformers, including 4-hydroxybenzoic acid (4HBA), trans-cinnamic 
acid (TCA), suberic acid (SUB), sebacic acid (SBC), 1-hydroxy-2-naphthoic acid (1H2N), and benzamide (BZD) were prepared.  
Methods: ITZ cocrystals was prepared by solvent evaporation process. The cocrystals produced were characterized using powder x-ray diffraction 
(PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and fourier transform infrared (FTIR) spectroscopy. Solubility 
analysis was performed to evaluate the cocrystals. 
Results: PXRD and DSC analysis revealed that the pattern of all ITZ cocrystals was distinguishable from the individual compounds which indicates 
the formation of new phase. The solubility of ITZ and its cocrystals from highest to lowest after 24 h in 0.1 N HCl solution (pH 1.2) follows the order 
ITZ-TCA (1.97-fold), ITZ-SBC (1.09-fold), ITZ, ITZ-1H2N (0.58-fold) and ITZ-4HBA (0.46-fold). 
Conclusion: This study demonstrates that the selection of coformers has pronounced an impact on the physicochemical properties of ITZ. Based on 
this study, it can be concluded that cocrystallization offers a valuable way to improve the solubility of ITZ. 
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Itraconazole (ITZ) is a potent synthetic triazole antifungal with 
activities against various fungal infections including histoplasmosis, 
blastomycosis and oncomycosis [1]. ITZ belongs to class II of the 
biopharmaceutics classification system (BCS) with low solubility and 
high permeability. Its aqueous solubility is estimated at 
approximately 1 ng/ml at neutral pH and 5 µg/ml at pH 1 which 
indicate a poor oral bioavailability (55%) [2]. Due to its extremely 
low solubility, there is a practical demand to improve the solubility 
and therefore the oral bioavailability of ITZ. Different strategies to 
improve the aqueous solubility and dissolution rate have been 
described in the literature, such as cyclodextrin complexation [3], 
solid dispersions [4] and self-emulsifying drug delivery system 
(SEDDS) [5]. In addition, adsorption on ordered mesoporous silica 
has also been reported by other researchers [6]. 
Crystal engineering has become one of the most effective strategies 
to improve the physicochemical properties of various active 
pharmaceutical ingredients (APIs). This concept has widely been 
explored in designing multicomponent solid forms of APIs which 
possess unfavorable physicochemical properties. Pharmaceutical 
polymorphs, cocrystals and salts formations are few examples on 
the utilization of crystal engineering of overcoming the poor 
solubility of several APIs [7]. Different polymorphic forms of ITZ 
were reported in previous publications, which showed three 
polymorphic forms of ITZ (forms I-III) [8, 9]. Salt formation is the 
first choice of method to increase solubility, dissolution rate and 
bioavailability of poorly soluble APIs [10]. Compared to other 
multicomponent crystals, such as cocrystals or eutectic mixtures, 
pharmaceutical salts are the most preferred solid-state form to 
achieve solubility enhancement [11]. Therefore, it is understandable 
that almost 50% of currently marketed APIs are in the form of salts 
[10]. However, salt formation is feasible to be done when the API 
possesses a suitable ionizable site [12]. The utility of salts is also 
limited by their hygroscopicity character due to the ionic nature of 
the crystal [13]. On the other hand, the salt formation of very weak 
base APIs such as ITZ also presents a greater risk of 
disproportionation [14]. 
During the past few years, interest in cocrystals research as an 
alternative way to modify the physicochemical properties of APIs 
has been increased significantly in the pharmaceutical sector. 
Pharmaceutical cocrystal may be defined as a molecular complex of 
an API with one or more cocrystal formers (CCFs) in a well-defined 
stoichiometry through hydrogen bonds or other non-covalent 
interactions, such as hydrogen bonds, π-π stacking, and van der 
Waals interactions [15]. Apart from the potential improvement in 
solubility aspect [16], pharmaceutical cocrystals have already been 
proven to be useful in improving stability [17], hygroscopicity [18], 
mechanical properties [19] and bioavailability, while still 
maintaining the pharmacological activity of the drug [20]. In 
addition, cocrystal formation also provides the opportunities for the 
pharmaceutical industry to create intellectual properties and 
patents of APIs to extend their life cycle [21].  
Pharmaceutical salts and co-crystals of ITZ with various counterions 
and coformers have previously been reported. Remenar et al. [22] 
synthesized ITZ cocrystals with 1,4-dicarboxylic acids (fumaric, 
succinic, l-malic, l-, d-and dl-tartaric acid) as the coformers. It was 
reported that ITZ-l-malic cocrystal showed a similar dissolution rate 
compared to the commercial product containing amorphous ITZ. 
Tarsa et al. [23] have reported the formation of ITZ cocrystals and 
salts with hydrochloric, fumaric, maleic, phosphoric, succinic and 
1,5-naphthalene disulfonic acids. The formation of ITZ ditosylate salt 
with enhanced solubility and dissolution rate has also been studied 
by Kumar et al. [24]. Futhermore, ITZ cocrystals with oxalic, adipic, 
malonic, glutaric and pimelic acids were successfully synthesized by 
other researchers [25].  
Crystal engineering strategies is applied in the preparation of novel 
cocrystals by the identification of a potential functional group, which 
can be utilized in the formation of supramolecular synthon. As 
shown in Scheme 1, ITZ possesses triazole group, which is well 
known to form robust O−H···N heterosynthons with carboxylic acids. 
Solvent evaporation is the most commonly used method for 
cocrystallization which includes supersaturation of the solution by 
evaporation, cooling or addition of solubility changing solvent 
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(solvent mixture or anti-solvent) [26]. In this work, novel 
pharmaceutical cocrystals of ITZ with 4-hydroxybenzoic acid 
(4HBA), trans-cinnamic acid (TCA), suberic acid (SUB), sebacic acid 
(SBC), 1-hydroxy-2-naphthoic acid (1H2N) and benzamide (BZD) 
were prepared by a solvent evaporation method (see Scheme 1). The 
physicochemical properties of the prepared ITZ cocrystals were 
further characterized by powder x-ray diffraction (PXRD), 
differential scanning calorimetry (DSC), thermogravimetric analysis 




Scheme 1: Experimental condition and product obtained with the stoichiometric ratio in the reaction between ITZ and coformers 
 
MATERIALS AND METHODS 
Materials 
Itraconazole (ITZ) was purchased from Metrochem API Pvt Ltd 
(Hyderabad, India). 4-hydroxybenzoic acid (4HBA), trans-cinnamic 
acid (TCA), suberic acid (SUB), sebacic acid (SBC), 1-hydroxy-2-
naphthoic acid (1H2N) and benzamide (BZD) were obtained from 
Sigma-Aldrich Co. (MO, USA). Tetrahydrofuran (ACS grade), 
trifluoroethanol (ACS grade), chloroform (ACS grade), trifluoroacetic 
acid (ACS grade) and acetonitrile (HPLC grade) were obtained from 
Merck KGaA (Darmstadt, Germany).  
Preparation of itraconazole-4-hydroxybenzoic acid cocrystal 
(ITZ-4HBA) 
Molar quantities of ITZ and 4HBA (1:2 mole ratio) were dissolved in 
20 ml trifluoroethanol and mixed under sonication at 40 °C for 30 min. 
The resulting solution was placed into a crystallizing disk and heated 
at 70 °C for 5 h using a hot plate to evaporate the solvent. The dried 
solid was collected and placed in the glass vial for further analysis. 
Preparation of itraconazole-trans-cinnamic acid cocrystal (ITZ-
TCA) 
Equimolar quantities of ITZ and TCA (1:1 mole ratio) were dissolved in 
20 ml tetrahydrofuran and mixed under sonication at 40 °C for 30 min. 
The resulting solution was placed into a crystallizing disk and heated at 
70 °C for 5 h using a hot plate to evaporate the solvent. The dried solid 
was collected and placed in the glass vial for further analysis. 
Preparation of itraconazole-suberic acid cocrystal (ITZ-SUB) 
Equimolar quantities of ITZ and SUB (1:1 mole ratio) were dissolved 
in 20 ml tetrahydrofuran and mixed under sonication at 40 °C for 30 
min. The resulting solution was placed into a crystallizing disk and 
heated at 70 °C for 5 h using a hot plate to evaporate the solvent. The 
dried solid was collected and placed in the glass vial for further 
analysis. 
Preparation of itraconazole-benzamide cocrystal (ITZ-BZD) 
Molar quantities of ITZ and BZD (1:2 mole ratios) were dissolved in 
20 ml tetrahydrofuran and mixed under sonication at 40 °C for 30 
min. The resulting solution was placed into a crystallizing disk and 
heated at 70 °C for 5 h using a hot plate to evaporate the solvent. The 
dried solid was collected and placed in the glass vial for further 
analysis. 
Preparation of itraconazole-1-hydroxy-2-naphthoic acid 
cocrystal (ITZ-1H2N) 
Molar quantities of ITZ and 1H2N (2: 1-mole ratios) were dissolved 
in 20 ml tetrahydrofuran and chloroform (1:1, v/v) solutions and 
mixed under sonication at 40 °C for 30 min. The resulting solution 
was placed into a crystallizing disk and heated at 70 °C for 5 h using 
a hot plate to evaporate the solvent. The dried solid was collected 
and placed in the glass vial for further analysis. 
Preparation of itraconazole-sebacic acid cocrystal (ITZ-SBC) 
Molar quantities of ITZ and SBC (1:2 mole ratios) were dissolved in 
20 ml tetrahydrofuran and chloroform (1:1, v/v) solutions and 
mixed under sonication at 40 °C for 30 min. The resulting solution 
was placed into a crystallizing disk and then heated at 70 °C for 5 h 
using a hot plate to evaporate the solvent. The dried solid was 
collected and placed in the glass vial for further analysis. 
Powder x-ray diffraction (PXRD) 
The PXRD patterns were collected by a Rigaku Ultima IV X-ray 
diffractometer (Rigaku Co., Tokyo, Japan) using Cu Kα radiation (λ = 
1.54 Å), a tube voltage of 40 kV and a tube current of 40 mA. Data 
were collected from 2 to 40 ° at a continuous scan rate of 4 °/min. 
Differential scanning calorimetry (DSC) 
Thermal analysis of the samples was performed on a DSC Q20 (TA 
Instruments Inc., New Castle, DE, USA) which was calibrated for 
temperature and cell constants using indium. Samples (2-5 mg) 
crimped in aluminum pans were analyzed from 50 to 250 °C at a 
heating rate of 10 °C/min. Samples were continuously purged with 
nitrogen at 50 ml/min. The peak transition temperatures of samples 
were analyzed using Universal Analysis software (TA Instruments 
Inc., New Castle, DE, USA). 
Thermogravimetric analysis (TGA) 
TGA was performed on a TGA Q50 (TA Instruments Inc., New Castle, 
DE, USA) instrument. Approximately 2-5 mg samples were heated 
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from 50 to 400 °C in open aluminium pans at a rate of 10 °C/min 
under a nitrogen purge at a flow rate of 50 ml/min. TGA data were 
analyzed using Universal Analysis software (TA Instruments Inc., 
New Castle, DE, USA). 
Fourier transform infrared (FTIR) spectroscopy  
FTIR spectra of the compounds were recorded on an FTIR type 
ALPHA infrared spectrometer (BRUKER, MA, USA) in platinum 
attenuated total reflectance (ATR) mode at a wavenumber range of 
4000-700 cm−1 with a resolution of 4 cm−1
Accurately weighed amount of each of ITZ cocrystal was dissolved in 
tetrahydrofuran. The solution was filtered through 0.22 µm PTFE 
syringe filter (Whatman, USA). ITZ contents were assayed by HPLC 
(n = 3). 
. 
High-performance liquid chromatography (HPLC)  
Concentrations of ITZ in solutions were determined by Waters 
Alliance HPLC system which includes Waters e2695 separation 
module, Waters 2489 UV detector and 4.6 × 150 mm Atlantis dC18, 5 
μm column (Waters Corporation, Milford, MA). The mobile phase 
consisted of acetonitrile: trifluroacetic acid 0.1% (55:45, %v/v) at a 
flow rate of 1.0 ml/min. ITZ was detected at 261 nm. The injection 
volume was 20 µl. Data acquisition and analysis were performed 
using Empower 2.0 software (Waters Corporation, Milford, MA). 
Determination of drug content  
Solubility measurements 
Excessive amount of samples (400 mg) were suspended in 0.1 N HCl 
solution (pH 1.2) using screw-capped glass vials. The suspensions 
were stirred using a magnetic stirrer at a temperature of 37 °C. After 
24 h, the suspensions were filtered through a paper filter at room 
temperature. Solid filtrates were then dried and used for further 
PXRD analysis. The resulting solutions were filtered again through a 
0.22 μm nylon syringe filter (Whatman, USA) at room temperature. 
The filtered aliquots were sufficiently diluted and concentrations of 
ITZ in solutions were further analyzed using HPLC. 
RESULTS AND DISCUSSION 
The formation of cocrystal or salt is generally guided by a thumb rule 
of ΔpKa (ΔpKa = pKa (base)-pKa(acid)) value between API and 
coformer. In a previous study [27], it is highlighted that if ΔpKa<−1, 
cocrystal formation is expected, whereas in the region ΔpKa>4, the salt 
is more common. If ΔpKa lies in between −1 ≤ ΔpKa ≤ 4 , then the 
prediction of proton transfer is ambiguous. With regards to the 
ambiguity, the resultant product may be a salt or cocrystal, therefore, 
the cocrystals are further needed to be analyzed [27]. The pKa values 
of ITZ and coformers and ΔpKa values are listed in table 1.
 
Table 1: pKa values of ITZ and organic acids 
Sample pKa ∆pKa 
ITZ 3.70 -- 
TCA 4.44 -0.74 
4HBA 4.54 -0.84 
SUB 4.15 -0.45 
1H2N 3.02 0.68 
SBC 4.72 -1.02 
BZD 23.35 -19.65 
 
Powder x-ray diffraction (PXRD) analysis 
PXRD is a reliable technique to identify the formation of a new 
crystalline phase in solid state. Every crystalline phase of a 
compound exhibited its own characteristic PXRD pattern, thus PXRD 
analysis is commonly used to distinguish the resulting products 
from the starting materials [28]. PXRD patterns of ITZ, coformers, 
physical mixture between ITZ and coformer (PM) and their 
multicomponent crystals are shown in fig. 1. The details of 
characteristic diffraction peaks are presented in table 2. PXRD 
spectrum in fig. 1 revealed that novel crystalline forms which were 
distinct from the starting components have been generated. This can 
be explained on the basis of changes in internal crystal structure due 
to the interaction between API and coformers [29]. 
 
 
Fig. 1: Powder X-ray diffractograms of ITZ and its cocrystal 
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Table 2: The characteristics diffraction peaks of ITZ, coformers and its multicomponent crystals 
 2θ (degrees) 
ITZ 14.140; 14.440; 17.500; 17.960; 20.340; 23.460 
TCA 8.840; 9.800; 18.400; 22.880; 25.380; 29.480 
ITZ-TCA 4.220; 14.300; 16.640; 18.520; 21.020; 23.560 
4HBA 17.640; 19.520; 22.080; 24.500; 26.880; 29.940 
ITZ-4HBA 10.320; 16.040; 19.560; 20.600; 20.840; 26.280 
SUB 9.960; 20.040; 21.540; 24.860; 28.740 
ITZ-SUB 3.980; 6.160; 12.960; 18.620; 19.520; 21.720 
1H2N 10.300; 12.120; 14.760; 17.080; 22.520; 26.480 
ITZ-1H2N 11.160; 16.980; 17.460; 18.720; 22.220; 22.880 
SBC 7.980; 19.440; 21.400; 23.980; 26.320; 29.980 
ITZ-SBC 14.080; 17.380; 20.400; 21.520; 22.320; 24.100 
BZD 8.020; 16.080; 18.060; 22.460; 26.600; 28.740 
ITZ-BZD 4.820; 11.080; 12.380; 16.480; 19.660; 21.580  
 
Thermal analysis 
Thermal analytical techniques, such as DSC and TGA, are commonly 
used to analyze the properties of a material and investigate the 
possible interactions between multiple components in a 
formulation. DSC is a very useful thermoanalytical method in the 
characterization of solid-state interactions between drug and 
coformers through the appearance, shifts or disappearance of 
endothermal effects [19]. DSC thermograms of ITZ, coformers and 
ITZ cocrystals are shown in fig. 2. Melting temperature data from 
DSC thermograms are summarized in table 3. The distinct cocrystals 
melting point compared to those of the individual components 
indicated the interaction between ITZ and coformers to produce 
novel crystalline phase. DSC thermograms of ITZ cocrystals, except 
ITZ-BZD and ITZ-SBC, showed a single and sharp melting endotherm 
which indicated the purity of cocrystals. In the case of ITZ-BZD 
cocrystal, an additional small endothermic peak can be observed 
after the melting point which may be caused by the decomposition, as 
confirmed by the TGA curve. Thermogram of ITZ-SBC also showed an 
additional small endothermic peak which is very close to the major 
endotherm at 123.50 °C which may be caused by the presence of small 
excess of starting compounds that forms the eutectic phase. The 
altered melting points of ITZ cocrystals as compared to ITZ and each 
coformers might be attributable to the intermolecular interaction 
(hydrogen bonding interaction) between API and coformers that 
might alter the packing arrangement, crystal lattice and change in 
crystal structure of molecules in the cocrystals [29, 30]. 
A statistical study by Perlovich [31] on 727 cocrystal systems 
indicated that majority of cocrystals (55.3%) had melting points in 
between those of the drug and coformers, while 15.8% of cocrystals 
possessed higher melting point and 28.9% showed lower melting 
point than those of individual compounds. An analysis of the 
correlation between melting points of coformers and cocrystals can 
provide simple rules for the rational choice of coformers in the 
design of cocrystals with desirable thermal properties [32]. Melting 
points of cocrystals were found to be correlated to melting points of 
coformers in a linear regression. A very good correlation coefficient 
of 0.9426 was found in this study (fig. 3), which means that melting 
points of cocrystals were well-correlated to the melting points of 
coformers. Therefore, it is possible to modify the melting point of 
ITZ cocrystals by considering the melting point of the coformers. 
Such association has previously been published for a series of AMG 
517 cocrystals with various acids [32]. 
 
 
Fig. 2: DSC thermograms of ITZ and its cocrystals 
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Table 3: Melting point of ITZ, coformers and ITZ cocrystals 
Sample Melting point of ITZ or coformers (°C) Melting point of ITZ cocyrstal (°C) 
ITZ 168.88 -- 
ITZ-TCA 133.97 142.35 
ITZ-4HBA 215.19 203.54 
ITZ-SUB 143.49 137.21 
ITZ-1H2N 194.77 173.84 
ITZ-SBC 134.87 123.50 
ITZ-BZD 126.75 125.61 
 
 
Fig. 3: Correlation between melting point (m. p) cocrystals versus melting point (m. p) coformers 
 
 
Fig. 4: TGA thermograms of (a) ITZ and coformers and (b) ITZ cocrystals (b.1 indicating zone of coformer’s elimination; b.2 indicating 
zone of ITZ decompotition or degradation) 
 
Table 4: Theoretical and experimental weight loss analysis in TGA 
Sample Mole ratio of ITZ: ccf Theoretical weight loss (%) Experimental weight loss (%) 
ITZ-TCA 1:1 17.35 16.99 
ITZ-4HBA 1:2 28.13 26.86 
ITZ-SUB 1:1 19.80 20.20 
ITZ-1H2N 1:1 21.06 18.40 
ITZ-SBC 1:2 36.44 37.10 
ITZ-BZD 1:2 25.56 23.84 
 
TGA was conducted to analyze the changes in cocrystal weight with 
regards to the changes in temperature (fig. 4a-b). Fig. 4b shows that 
TGA curves can be divided into two zones that imply the 
decomposition of ITZ cocrystals in a two-step process. The first 
thermal event is a step of weight loss that agreed well (in 
percentiles) to the coformer composition in cocrystal, indicating that 
this component (coformer) is released prior to decomposition of the 
residual ITZ (table 4, fig. 4b). Similar behavior has been reported 
previously for a series of cocrystals with AMG 517 [32] and 
acetazolamide [33]. 
Fourier transform infrared (FTIR) spectroscopy 
Fourier transform infrared (FTIR) spectroscopy analysis can be used 
to verify the formation of multicomponent crystals. The changes in 
vibrational frequencies of specific functional groups of the product 
compared to their starting components can be directly correlated 
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with the changes in hydrogen bonding due to formation of 
multicomponent crystals [34]. The FTIR spectra for ITZ, coformers 
and ITZ cocrystal are shown in fig. 5a, and table 5 represents the list 
of relevant IR bands of ITZ, coformers and cocrystals [35]. The 
comparison of FTIR spectrum between ITZ cocrystals and the 
starting components showed numerous changes which indicate the 
obtained new multicomponent crystal. 
In the formation of ITZ-TCA, ITZ-4HBA, ITZ-SUB, ITZ-1H2N and ITZ-
SBC, the changes in O−H stretching frequency imply that these 
functional groups participate in the hydrogen bonds which resulted 
in new multicomponent crystals formation. Based on the changes in 
the frequency of these functional groups, we hypothesized that ITZ 
and those coformers were involved in strong O−H··· N hydrogen 
bond to form new multicomponent crystals (fig. 5b). On the other 
hand, the shifting in spectral peaks have also been observed for the 
NH2
FTIR analysis can also be used to determine whether proton transfer 
from carboxylic acids had occurred, which can be used to 
differentiate the formed product between salt and cocrystal. 
Generally, the carbonyl stretch C=O of carboxylic acid (COOH) 
showed an intense band at 1750-1680 cm
 scissor and rocking mode functional groups in ITZ-BZD which 
indicate its participation in the hydrogen bonding between the ITZ 
and BZD. We hypothesized that strong N−H···N hydrogen bond was 
likely to be involved in the formation of new ITZ-BZD 
multicomponent crystals (fig. 5b). 
−1. In the formation of a 
salt species, there was a typical carboxylate anion which have two 
carbonyl stretching bands, i.e. a strong asymmetrical band below 
1600 cm-1 and a weaker symmetrical band near 1400 cm-1 [35,36]. 
The carbonyl group of TCA, 4HBA, SUB, 1H2N and SBC in new ITZ 
multicomponent crystals exhibits a distinct peak at 1680-1710 cm-1
 
, 
indicating that the carboxylic acid group is neutral rather than 
negatively charged. Therefore, proton transfer does not occur 
between ITZ and organic acids that were used in this study, thus 
confirming that cocrystal were formed. 
 
Fig. 5: FTIR spectra of (a) ITZ and its cocrystals and (b) heterosynthons in ITZ cocrystals 
 
Table 5: FTIR stretching frequencies (cm-1
Functional group 
) of ITZ and its cocrystals 
Frequency (cm-1) 
ITZ ITZ-TCA ITZ-4HBA ITZ-SUB ITZ-1H2N ITZ-SBC ITZ-BZD 















C=O stretch 1695.78 1710.87 1681.41 1695.96 1683.51 1687.38 1693.98 
C–N stretch 1452.98 1451.88 1450.43 1451.24 1449.67 1450.72 1447.44 
C=N stretch 1613.30 1648.81 1597.12 1610.46 1633.23 1584.54 1647.32 
NH2 –  scissor – – – – – 1611.17 
NH2 –  rocking – – – – – 1134.04 
 
Table 6: Theoretical and experimental drug content analysis in ITZ cocrystal 
Sample Mol ratio Theoretical Experimental 
% ITZ % coformer % ITZ % coformer 
ITZ-TCA 1:1 82.65 17.35 83.37 16.63 
ITZ-4HBA 1:2 71.87 28.13 68.25 31.75 
ITZ-SUB 1:1 80.20 19.79 80.71 19.28 
ITZ-1H2N 1:1 78.94 21.06 78.02 21.98 
ITZ-SBC 1:2 63.56 36.44 61.11 38.89 
ITZ-BZD 1:2 74.44 25.56 70.46 29.54 
Determination of drug content 
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ITZ content in the ITZ cocrystals was determined by HPLC. The 
percentage of ITZ content in cocrystals is shown in table 6. 
Analysis of solubility and stability in solution 
Solubility is defined as the concentration of a substance in solution 
that is at equilibrium with an excess amount of the undissolved 
substance [37]. Solubility has a significant impact on the 
bioavailability of API with poor aqueous solubility. ITZ is a BCS class 
II drug with low aqueous solubility, thus the formation of cocrystal 
with high aqueous solubility and good stability is desirable to 
improve its bioavailability. In order to evaluate the solubility of ITZ 
cocrystals, slurry experiments were performed in 0.1 N HCl solution 
(pH 1.2) at 37 °C for 24 h (results are shown in table 7). Solubility of 
ITZ-BZD and ITZ-SUB could not be determined since the cocrystal 
was partially converted to ITZ within 24 h (table 7, fig. 6). ITZ-TCA 
cocrystal showed the highest solubility, which is 1.97 times higher 
than the solubility of ITZ. ITZ-SBC cocrystals showed slight 
improvements in the solubility of ITZ. In the case of other ITZ 
cocrystals (ITZ-1H2N and ITZ-4HBA), solubility were found to be 
lower than the solubility of ITZ. It has been previously proposed that 
cocrystal solubility is directly proportional to the solubility of its 
components, thus for solubility improvement, it is a common strategy 
to employ a coformer with a high aqueous solubility in order to 
cocrystallize with a poorly soluble drug [38]. In this study, coformer 
solubilities did not show a clear correlation with cocrystal solubilities 
[39]. It is interesting that the melting point (m. p) of the cocrystals in 
this study showed a semi-empirical inverse relationship to the 
solubility (fig. 7). Except for the ITZ-SBC cocrystal, there is an inverse 
correlation between the melting points of the cocrystals and their 
solubilities. ITZ-4HBA exhibits the highest melting point and hence the 
lowest solubility. Similar results have also been reported previously by 
other researchers for other APIs [38, 40]. 
 
Table 7: Solubility of ITZ, coformers and ITZ cocrystals in 0.1N HCl (pH=1.2) at 37 °C 
Sample Solubility of ITZ or coformers (ppm) Solubility of ITZ cocrystal (ppm) 
ITZ 5 --- 
ITZ-TCA 546 9.846±0.04 (x1.97) 
ITZ-SBC 1000 5.439±0.08 (x1.09) 
ITZ-1H2N 100 2.935±0.04 (x0.58) 
ITZ-4HBA 5000 2.307±0.12 (x0.46) 
*The values in the parenthesis specifies the extent of increase in solubility of ITZ molecules in cocrystals relative to the pure ITZ 
 
 
Fig. 6: Powder X-ray diffractograms of ITZ cocrystals before and after solubility study in 0.1N HCl (pH=1.2) at 37 °C (AS) 
 
 
Fig. 7: Correlation plot between solubility of cocrystals vs 
melting point of cocrystals 
CONCLUSION 
In summary, we reported the synthesis of six new cocrystals of 
itraconazole (ITZ-4HBA, ITZ-TCA, ITZ-SUB, ITZ-SBC, ITZ-1H2N and 
ITZ-BZD). The solid-state properties of ITZ cocrystals were 
systematically evaluated by PXRD, DSC, TGA, and FTIR analysis. The 
solubility of ITZ cocrystals can be either improved or decreased 
compared to pure ITZ. The improved solubility of ITZ-TCA (1.97-fold), 
and ITZ-SBC cocrystals (1.09-fold) and decreased the solubility of ITZ-
1H2N (0.58-fold) and ITZ-4HBA cocrystals (0.46-fold) as compared to 
the pure ITZ were determined after 24 h in 0.1 N HCl solution (pH 1.2) 
at 37 °C. Thus, this study proved cocrystallization to be a promising 
alternative in positively modifying the solubility of ITZ. 
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